EXELIXIS, INC.
At today's price, EXELIXIS, INC. (EXEL) is priced for +3.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Exelixis is a profitable oncology company built on the cabozantinib franchise, which generated $555 million of net product revenue in the first quarter of 2026, supplemented by ex-U.S. royalties that reached $179.2 million in 2025 ⟦"of royalties on net sales of cabozantinib products outside of the U.S."⟧. • The biggest specific risk is concentration plus the patent cliff: nearly all revenue comes from one drug, and the filing flags ⟦"The timing of the entrance of generic competitors to CABOMET
Is EXEL overvalued? See what's priced in →
674 institutional managers reported holding EXEL in 13F filings for the quarter ended 2026-03-31. 89 opened new positions that quarter. Held by BlackRock, Vanguard Group, Renaissance Technologies, among others. On the short side, 30.6M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (13.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
EXEL has cut its share count 17.8% over the past five years, spending $2.58B on repurchases. It pays no dividend. Cash returned over the past three years: $2.46B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at EXEL over the trailing three years: 2023: 1 buy totaling $2.60M; 2024: 3 buys totaling $12.67M; 2025: 1 buy totaling $1.19M. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
EXEL's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | +1.8% | -0.1% |
| 2023-08-02 | +3.2% | +7.0% |
| 2023-11-02 | -2.2% | +17.3% |
| 2024-05-01 | -7.6% | +0.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
EXEL's latest 8-K filings: 2026-05-29 (items 5.02, 5.07, 9.01); 2026-05-05 (items 2.02, 8.01, 9.01); 2026-02-10 (items 2.02, 9.01); 2026-01-12 (items 2.02, 9.01); 2025-11-07 (items 5.02, 8.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.